Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
50
WGS Quote, Financials, Valuation and Earnings
Last price:
$140.43
Seasonality move
:
73.34%
Day range:
$136.55 - $141.00
52-week range:
$55.17 - $170.87
Dividend yield:
0%
P/E ratio:
2,329.02x
P/S ratio:
10.01x
P/B ratio:
13.89x
Volume:
282.1K
Avg. volume:
467.5K
1-year change:
86.51%
Market cap:
$4.1B
Revenue:
$305.5M
EPS (TTM):
$0.06
Analysts' Opinion
-
Consensus RatingGeneDx Holdings Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $169.78, GeneDx Holdings Corp. has an estimated upside of 20.89% from its current price of $140.44.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $153.00 representing 100% downside risk from its current price of $140.44.
Fair Value
-
According to the consensus of 8 analysts, GeneDx Holdings Corp. has 20.89% upside to fair value with a price target of $169.78 per share.
WGS vs. S&P 500
-
Over the past 5 trading days, GeneDx Holdings Corp. has underperformed the S&P 500 by -7.4% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
GeneDx Holdings Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
GeneDx Holdings Corp. has grown year-over-year revenues for 7 quarters straight. In the most recent quarter GeneDx Holdings Corp. reported revenues of $116.7M.
Earnings Growth
-
GeneDx Holdings Corp. has grown year-over-year earnings for 11 quarters straight. In the most recent quarter GeneDx Holdings Corp. reported earnings per share of -$0.27.
Enterprise value:
4B
EV / Invested capital:
--
Price / LTM sales:
10.01x
EV / EBIT:
364.84x
EV / Revenue:
9.99x
PEG ratio (5yr expected):
--
EV / Free cash flow:
259.84x
Price / Operating cash flow:
260.42x
Enterprise value / EBITDA:
115.10x
Gross Profit (TTM):
$264.5M
Return On Assets:
0.46%
Net Income Margin (TTM):
0.52%
Return On Equity:
0.82%
Return On Invested Capital:
0.56%
Operating Margin:
-2.68%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $206.5M | $267.2M | $402.2M | $76.9M | $116.7M | |
| Gross Profit | $4.6M | $140.5M | $264.5M | $43.4M | $79.4M | |
| Operating Income | -$247.5M | -$54.2M | $11M | -$7.4M | -$3.1M | |
| EBITDA | -$183M | -$30.1M | $34.9M | -$1.2M | $3.4M | |
| Diluted EPS | -$32.74 | -$3.17 | $0.06 | -$0.31 | -$0.27 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $538.5M | $306.6M | $171.8M | $186M | $237.6M | |
| Total Assets | $603.4M | $829M | $417.3M | $408.8M | $493.9M | |
| Current Liabilities | $71.4M | $162.3M | $68.4M | $77.3M | $87.6M | |
| Total Liabilities | $212.1M | $267.7M | $163M | $204.3M | $201.6M | |
| Total Equity | $391.3M | $561.3M | $254.3M | $204.5M | $292.3M | |
| Total Debt | $11M | $75.5M | $73.8M | $113.6M | $110M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$214.9M | -$55.2M | $33.2M | -$4.4M | $15.8M | |
| Cash From Investing | -$41.7M | -$34.5M | -$51M | -$7.8M | -$4.7M | |
| Cash From Financing | $139.2M | $60.2M | $55.9M | $14M | $10.8M | |
| Free Cash Flow | -$221.1M | -$60M | $15.5M | -$5M | $9.6M | |
WGS
Sector
Market Cap
$4.1B
$27.9M
Price % of 52-Week High
82.19%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-1.92%
-1.49%
1-Year Price Total Return
86.51%
-16.66%
Beta (5-Year)
2.025
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$146.31
200-day SMA
Buy
Level
$106.53
Bollinger Bands (100)
Buy
Level
114.75 - 145.93
Chaikin Money Flow
Sell
Level
-68.1K
20-day SMA
Sell
Level
$155.22
Relative Strength Index (RSI14)
Sell
Level
42.49
ADX Line
Sell
Level
18.53
Williams %R
Neutral
Level
-78.6508
50-day SMA
Buy
Level
$140.24
MACD (12, 26)
Buy
Level
25.94
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
202.3K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.6873)
Sell
CA Score
(Annual)
Level (-0.396)
Buy
Beneish M-Score
(Annual)
Level (-2.6525)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (2.138)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
GeneDx Holdings Corp. operates as a health intelligence company. It engages in healthcare with the use of its collected disease data sets. It offers exome and genome testing for diagnosis of genetic disease. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
Stock Forecast FAQ
In the current month, WGS has received 7 Buy ratings 1 Hold ratings, and 0 Sell ratings. The WGS average analyst price target in the past 3 months is $169.78.
-
Where Will GeneDx Holdings Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that GeneDx Holdings Corp. share price will rise to $169.78 per share over the next 12 months.
-
What Do Analysts Say About GeneDx Holdings Corp.?
Analysts are divided on their view about GeneDx Holdings Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that GeneDx Holdings Corp. is a Sell and believe this share price will drop from its current level to $153.00.
-
What Is GeneDx Holdings Corp.'s Price Target?
The price target for GeneDx Holdings Corp. over the next 1-year time period is forecast to be $169.78 according to 8 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is WGS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for GeneDx Holdings Corp. is a Buy. 7 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of WGS?
You can purchase shares of GeneDx Holdings Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase GeneDx Holdings Corp. shares.
-
What Is The GeneDx Holdings Corp. Share Price Today?
GeneDx Holdings Corp. was last trading at $140.43 per share. This represents the most recent stock quote for GeneDx Holdings Corp.. Yesterday, GeneDx Holdings Corp. closed at $140.44 per share.
-
How To Buy GeneDx Holdings Corp. Stock Online?
In order to purchase GeneDx Holdings Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get WGS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
WGS
Sector
P/E ratio
2,329.02x
23.85x
PEG ratio
--
-0.01x
P/B ratio
13.89x
1.81x
Price / LTM sales
10.01x
1.58x
Growth Metrics
WGS
Sector
Revenue growth
51.86%
4.62%
Earnings growth
13.59%
10.5%
Revenue (5-year growth)
9.26%
6.5%
Earnings forecast
-$0.01
-$0.21
Profitability
WGS
Sector
Profitability FY 2024
$176.5M
$3.6M
Return on invested capital
0.56%
-31.87%
Return on assets
0.46%
-28.18%
Return on equity
0.82%
-37.63%
Earnings Date
Last Earnings Date
Oct
28
Next Earnings Date
Feb
17
Estimated Next Earnings Date
Jan
27
Balance Sheet
WGS
Sector
Total cash
$155.1M
$26.4M
Short term investments
$56M
$25.7M
Total assets
$464.7M
$76.9M
Long term debt
$110M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
